Celebration of safety- and efficacy data from the last preclinical study
The team and network of Ilya Pharma took the opportunity to round off a great year by getting together in the new office in Uppsala Science Park.
-We celebrate both a good year and especially that a large milestone was accomplished successfully, says the CEO Evelina Vågesjö.
The milestone is more specifically a tox-study, the last preclinical study in the project, that was preformed during the spring. Treatment of wounds with the drug candidate, ILP100, was proven safe on all parameters and it was demonstrated that the treatment accelerates wound healing and reduces scaring also in this model.
-The data reflects what we expected and now we have full focus on the phase I clinical trial. I really look forward to the coming 12 months and we have a very skilled team taking the project to clinical phase and in parallel continue to develop the company in a smart way, Evelina Vågesjö continues.